Bromodomain Pharmaceuticals Inc is categorized under Commercial Biotechnical Research in Old Greenwich, CT and active since 2013.
Bromodomain Pharmaceuticals Inc was established in 2013, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Ming-Ming Zhou at the company’s single location by writing to 35 Richmond Drive, Old Greenwich, Connecticut CT 06870 or by phoning (203) 637-7426. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Bromodomain Pharmaceuticals Inc |
Contact Person: | Ming-Ming Zhou |
Address: | 35 Richmond Drive, Old Greenwich, Connecticut 06870 |
Phone Number: | (203) 637-7426 |
Annual Revenue (USD): | $100.000 to $499.999 |
Founded: | 2013 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2B (Business to Business) |
Business Category: | Commercial Biotechnical Research |
SIC Code: | 8731 |
NAICS Code: | 541711 |
Share This Business: |
Bromodomain Pharmaceuticals Inc was started in 2013 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Ming-Ming Zhou for inquiries that concern Bromodomain Pharmaceuticals Inc by calling the company number (203) 637-7426, as your correspondence is most welcome. Additionally, the physical location of the single location of Bromodomain Pharmaceuticals Inc can be found at the coordinates 41.042187,-73.569007 as well as the street address 35 Richmond Drive in Old Greenwich, Connecticut 06870.
For its online presence, you may visit Bromodomain Pharmaceuticals Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.